“Building A World Class Genetics Center Based On Data Scalability” – Forbes

Jun 7, 2020

by Randy Bean – The ability to accelerate drug discovery is necessary. I recently spoke with Jeffrey Reid, Head of Genomics and Data Engineering for Regeneron. Reid works in the Regeneron Genetics Center (RGC), a research initiative that seeks to improve patient care by using genomic approaches to speed drug discovery and development. The genetics center is a unit of Regeneron (NASDAQ: REGN), a leading biotechnology company that has been at the forefront of drug discovery for 3 decades. The firm’s focus on translating science into medicine has led to seven FDA-approved treatments. The Regeneron Genetics Center is engaged in one of the largest genetics sequencing efforts in the world.

Boston | New York | San Francisco | Raleigh
© 2020 NewVantage Partners. All rights reserved.